BMO Capital: 'Extraordinary General Meeting Sets the Stage for Novo Nordisk (NVO) Transformation'
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $50.00 price target on Novo Nordisk (NYSE: NVO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
